Bionovo received a response to a formal dispute appeal with the FDA, stating that MF101 is approvable if safety and efficacy were to be demonstrated in clinical testing. More so, the FDA stated clearly and unambiguously that the CMC package and the 10 batch records for MF101, Bionovo provided for the Phase 3 clinical testing were accepted by the Agency."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.